ACAD has done a great job here. As the company have previously said, they only have to repeat P2 trial. This is best outcome for all. The drug gets to those who need it quicker.
The trial will be enrolled quickly. Parents will be lining up to get started.
Becoming a really strong buy now.
ACAD has done a great job here. As the company have previously...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.80 |
Change
-0.830(5.31%) |
Mkt cap ! $1.891B | |||
| Open | High | Low | Value | Volume |
| $15.65 | $15.72 | $14.76 | $11.61M | 772.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1392 | $14.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.90 | 1553 | 2 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |